Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Niyati Skaria

Pediatric Endocrinology Sacramento, CA Medical Doctor

NPI 1720235146 CMS profile 611394

3814 Auburn Blvd, Suite 72, Sacramento, CA 95821

Open in the dashboard

General payments

$6,428

379 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Niyati Skaria of Sacramento, CA is reported in the CMS Open Payments database as having received $6,428 across 379 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $676 20
2024 General $529 30
2023 General $1,355 89
2022 General $1,432 87
2021 General $902 62
2020 General $507 29
2019 General $1,027 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Niyati Skaria
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Niyati Skaria were reported at $676. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Niyati Skaria Pediatric Endocrinology median Middle half National median
2019 $1,027 $196 $68–$845 $163
2020 $507 $124 $37–$722 $114
2021 $902 $134 $35–$691 $132
2022 $1,432 $177 $47–$726 $149
2023 $1,355 $236 $75–$887 $160
2024 $529 $259 $91–$979 $164
2025 $676 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,016 170 payments
  2. Tandem Diabetes Care, Inc. $745 30 payments
  3. Alexion Pharmaceuticals, Inc. $396 13 payments
  4. Novo Nordisk Inc $359 26 payments
  5. Insulet Corporation $318 14 payments
  6. Abbott Laboratories $268 12 payments
  7. Ascendis Pharma, Inc. $267 6 payments
  8. BioMarin Pharmaceutical Inc. $231 16 payments
  9. Dexcom, Inc. $212 11 payments
  10. TOLMAR Pharmaceuticals, Inc. $175 18 payments
  11. Other $1,440 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,358 366 payments
  2. Education $69 13 payments
Products named General payments · program years 2019–2025
  1. LUPRON DEPOT Endocrinology $1,723 152 payments
  2. t:slim X2 Insulin Pump with Control-IQ $553 16 payments
  3. STRENSIQ $303 9 payments
  4. SKYTROFA $267 6 payments
  5. Omnipod $245 11 payments
  6. FreeStyle Libre 3 $222 10 payments
  7. FENSOLVI $221 14 payments
  8. LUPRON DEPOT Endocrinology $172 11 payments
  9. Norditropin $149 7 payments
  10. BAQSIMI $138 6 payments
  11. Other $2,665 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

379 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record